Scientists have discovered a new regulator — called NHR-49 — that may shed light and open potential new therapeutic avenues to prevent the formation of toxic protein clumps, a hallmark of aging-related diseases, including Parkinson’s disease. Using embryos of the roundworm Caenorhabditis elegans, they found that NHR-49 is activated…

Phasing out fossil fuels could save an estimated 5.1 million lives each year worldwide by preventing deaths attributed to ambient air pollution, including those likely due to neurodegenerative diseases such as Parkinson’s, a study has found. Transitioning to clean, renewable energy sources is not only an effective intervention to…

InMed Pharmaceuticals will launch a new program – the INM-900 series – that will investigate the therapeutic potential of its cannabinoid analogs in neurodegenerative diseases, including Parkinson’s, the company announced in a press release. Cannabinoids, also called phytocannabinoids, are the active chemicals that give the cannabis plant…

The first participant has been dosed in a Phase 2 clinical trial testing IkT-148009, an experimental oral therapy for Parkinson’s disease being developed by Inhibikase Therapeutics. This step “represents a major milestone in the development of IkT-148009 for the treatment of Parkinson’s disease and related disorders,” Milton Werner,…

A Stanford University research initiative will focus on the causes of neurodegeneration in diseases such as Parkinson’s and on the mechanisms behind some people’s brain resilience to aging and neurodegeneration. This information will be used to find ways to prevent, delay, or even reverse neurodegeneration and cognitive decline. “This…

I lost most of my vision two years ago and became legally blind. It was devastating. Through the course of rehabilitation with a low vision clinic, I was taught how to see in a very new way, called eccentric viewing. Eccentric viewing is a method by which a…

Vanqua Bio has raised $85 million in funding to accelerate the development of its small molecule technology platform for treating neurodegenerative disorders such as Parkinson’s disease. Led by Omega Funds, the Series B financing will advance the research of Dimitri Krainc, MD, PhD, of Northwestern University, an…

The Silverstein Foundation for Parkinson’s with GBA is supporting early work by AcureX Therapeutics to bring into patient testing potential disease-modifying treatments for Parkinson’s disease. Specifically, grant funding will go to advance the development of small molecule compounds targeting the path involving a specific protein in mitochondria — the…

The Adira Foundation is inviting people with neurodegenerative diseases and their caregivers to join a grant proposal review committee. A nonprofit foundation, its mission is to unite people affected by some of most common neurodegenerative diseases — namely, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and…

An almost €2 million (about $2.3 million) EU-funded project is advancing the understanding of how damaged or abnormal cell parts are removed at the synapses, a process known as synapse-specific autophagy, and how defects in this mechanism contribute to neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s. Synapses,…